
AxoGen (AXGN) Stock Forecast & Price Target
AxoGen (AXGN) Analyst Ratings
Bulls say
Axogen Inc has demonstrated a positive financial trajectory, marked by a compound annual growth rate (CAGR) of 13.6% in revenue since 2020, reflecting strong market demand for its peripheral nerve repair technologies. The company benefits from increasing reimbursement rates, with the physician fee schedule for allograft procedures rising to $876 in 2025, a 9% increase since 2019, alongside a substantial 138% rise in average reimbursement for these procedures in ambulatory surgery centers, now averaging $4,565. This combination of consistent revenue growth and improving reimbursement dynamics positions Axogen favorably within the healthcare market, enhancing its potential for long-term success.
Bears say
Axogen Inc faces significant risks that could adversely impact its sales growth, including competitive pressures, regulatory challenges, and technological obsolescence, which may result in lower-than-expected revenue. Additionally, the company's reliance on securing regulatory approval for its flagship product, Avance, as a biologic presents a crucial hurdle alongside its historical net losses and dependency on key management for success. Furthermore, operational challenges such as difficulties in scaling production, maintaining quality, and addressing supply chain constraints could further undermine Axogen's ability to achieve sustainable profitability and expand its market presence.
This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.
AxoGen (AXGN) Analyst Forecast & Price Prediction
Start investing in AxoGen (AXGN)
Order type
Buy in
Order amount
Est. shares
0 shares